ISARIC Clinical Data Report 4 October 2020
Pritchard M., Dankwa E., Hall M., Baillie K., Carson G., Docherty A., Donnelly C., Dunning J., Fraser C., Hardwick H., Harrison E., Holden K., Kartsonaki C., Kennon K., Lee J., McLean K., Openshaw PJM., Plotkin D., Rojek A., Russell C., Semple M., Sigfrid L., Horby P., Olliaro P., Merson L., Partners OBOTISARICC.
Abstract ISARIC (International Severe Acute Respiratory and emerging Infections Consortium) partnerships and outbreak preparedness initiatives enabled the rapid launch of standardised clinical data collection on COVID-19 in Jan 2020. Extensive global uptake of this resource has resulted in a large, standardised collection of comprehensive clinical data from hundreds of sites across dozens of countries. Data are analysed regularly and reported publicly to inform patient care and public health response. This report is a part of a series and includes the results of data analysis on 4 October 2020. We thank all of the data contributors for their ongoing support. Report highlights include ISARIC collaborators recorded symptoms from over 102,000 patients in hospital with COVID-19. Most had fever, cough or shortness of breath. Children and older adults were less likely to display typical symptoms, and over 40% of patients >80 years experienced confusion. The ISARIC international database continues to grow. Data have been entered for 102,959 individuals from 566 sites across 42 countries. The analysis detailed in this report only includes individuals: for whom data collection commenced on or before 14 September 2020. (We have applied a 14-day rule to focus analysis on individuals who are more likely to have a recorded outcome. By excluding patients enrolled during the last 14 days, we aim to reduce the number of incomplete data records and thus improve the generalisability of the results and the accuracy of the outcomes. However, this limits our focus to a restricted cohort despite the much larger volumes of data held in the database.) AND who have laboratory-confirmed or clinically-diagnosed SARS-COV-2 infection. For the 88 , 463 cases who meet eligibility criteria for this report: ∘ The median age is 72 years. ∘ A total of 18% of patients were admitted at some point during their illness into an intensive care unit. ∘ Antibiotic use is high (82.2% of patients received antibiotics - the choice of antibiotic and specific indication have not yet been determined.) ∘ Fever, shortness of breath, a non-productive cough and fatigue were the most common symptoms. ∘ Altered consciousness/confusion was also relatively frequent (19,619/86,175) and most common in elderly patients. Overall, elderly patients are less likely to present with URTI symptoms. To access previous versions of ISARIC COVID-19 Clinical Data Report please use the link below: https://isaric.tghn.org/COVID-19-Data-Management-Hosting/evidence-reports/